Which closed-end funds own Samsung Biologics Co. Ltd.?
2 active closed-end funds report this security in their latest N-PORT filing, with a combined reported value of $4M. Security type: common equity. Country: South Korea. ISIN KR7207940008 · ticker 207940.KS.
Holdings are historical filings (report dates Jun 30, 2026; N-PORT becomes public ~60 days after quarter end), not live positions. Weights are percent of each fund’s net assets. Different instruments of one issuer (shares, bonds, preferreds) are separate securities — see related securities below.
Funds holding this security
| Fund | Category | Weight | Value (USD) | Balance | Fund net assets | Prem/disc | Report date |
|---|---|---|---|---|---|---|---|
| KF Korea Fund | International Equity | 0.77% | $2.8M | 3,100 sh | $365M | 15.4% discount | Jun 30, 2026 |
| AEF abrdn Emerging Markets ex-China Fund | International Equity | 0.25% | $1.2M | 1,285 sh | $461M | 6.2% discount | Jun 30, 2026 |
2 positions. Source: SEC Form N-PORT via market-data vendor re-serve. Funds without an N-PORT on file cannot appear here.
Also listed in filings as: Samsung Biologics Co Ltd.
Issuer-level search for “207940.KS” → · Compare two funds’ portfolios →